Author
Affirmative action in higher education may soon be abolished by the Supreme Court. The consequences for the physician workforce may be dire.
A review of key decisions from the Supreme Court’s 2021-2022 term, including rulings on abortion, concealed carry, and regulatory authority.
An ongoing patent battle over omega-3 fatty acids may have broad implications for the marketing of generic drugs.
For the generic drug and biosimilar industries, the Supreme Court’s recent decision in United States v. Arthrex, Inc. comes as a relief.
How the Court decides United States v. Arthrex will have important implications for patent law and for administrative law more generally.
Three developments may have effects on the use of patents to fend off competition for therapeutic monoclonal antibodies.
Over a decade after being recalled, rofecoxib received orphan drug designation for the treatment of pain caused by hemophilic arthropathy.
By Gregory Curfman This new post by Gregory Curfman appears on the Health Affairs Blog in a series stemming from the Fifth Annual Health Law Year in P/Review event held at Harvard Law School on Monday, January 23, 2017. With health care spending approaching…
By Gregory Curfman Just when the Affordable Care Act (ACA) has won a second major Supreme Court victory in King v. Burwell, conservative critics of the ACA are back on the attack, this time directing…
By Gregory Curfman Bill of Health contributor Gregory Curfman has a new piece up at the Health Affairs Blog discussing the Supreme Court’s decision in King v. Burwell in the broader context of Americans’ right to care. From the…
